Loading...
Loading...
Browse all stories on DeepNewz
VisitWhich cancer type will EnteroMix first be approved to treat by June 2025?
Breast Cancer • 25%
Lung Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Official announcements from the Russian Ministry of Health or credible medical publications
Russia to Launch Free mRNA Cancer Vaccine in 2025 with 75-80% Tumor Reduction
Dec 17, 2024, 10:01 PM
Russia has announced the development of a cancer vaccine that will be distributed free of charge to cancer patients starting in early 2025. The vaccine, developed by the Ministry of Health in collaboration with the Engelhardt Institute of Molecular Biology and the Gamaleya National Research Center, is reportedly a personalized mRNA-based treatment designed to slow tumor progression and reduce tumor size by up to 75-80%. According to Andrey Kaprin, Chief Oncologist of the Ministry of Health, the vaccine will be offered to patients who have exhausted other treatment options. The clinical trials for the vaccine, named 'EnteroMix,' are set to begin soon, with candidates being selected from patients aged 18 to 75 who have histologically confirmed tumors. The vaccine is not intended for prevention in the general population but will be tailored to treat individual cancer patients. The cost of production is estimated at 300,000 rubles per dose, but it will be provided free to Russian citizens. It remains unclear which specific types of cancer the vaccine is designed to treat.
View original story
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Mesothelioma • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Other • 25%
Successful with expected results • 25%
Partially successful • 25%
Unsuccessful • 25%
Results inconclusive • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Lymphoma • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
NTRK gene fusion cancers • 25%
RET fusion-positive cancers • 25%
Both equally • 25%
Neither • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 25% • 25%
25% to 50% • 25%